Hospital acquired infections (HAIs) are one of the leading cause of death across the globe. They are also referred to as nosocomial infections or Healthcare-associated Infections. According to Centers for Disease Control and Prevention (CDC), 1 out of every 25 hospital admitted patient gets contracted with HAIs. Moreover, in the U.S., in 2011, around 75,000 hospitalized patients died from HAIs. The global hospital acquired therapeutics market has observed a significant growth owing to rising number of hospital admitted patients and improved diagnostics capable of differentiating different strains of microbes. Complacency among healthcare providers and poor maintenance of hygiene are the two major preventable causes leading to HAIs. The global market is facing significant challenges such as growing antimicrobial resistance among certain strains of bacteria eg. Methicillin-Resistant Staphylococcus Aureus (MRSA). The major drivers of global hospital infection therapeutics market are the rising number of hospital admitted patients, poor infrastructure, understaffing and insufficient hospital equipment, overcrowding and lack of knowledge about blood transfusion safety measures, and rising geriatric population. However, stringent regulatory requirement, high cost of treatment and lack of transparent reimbursement scenario, are likely to hinder the market growth.
The global hospital infection therapeutics market is segmented on the basis of drug type, application, and geography. On the basis of drug type, the market is segmented into Antibiotics Drugs, Antifungal Drugs, Antiviral Drugs and Others. According to application, the global market is segmented into, Bloodstream Infections, Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Disorders and Other Hospital Infections. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. New drug approval and acquisitions are key strategies adopted by the top industry players. For instance FDA approved a new drug named Oritavancin, an intravenous antibiotic, for the treatment of drug-resistant bacteria, including MRSA. Merck & Co. has acquired Cubist Pharmaceuticals, a company with late-stage pipeline focusing on healthcare-acquired bacterial infections. The companies profiled in the report include, Sanofi S.A., GlaxoSmithKline plc, AstraZeneca plc, Merck & Co., Inc., Pfizer, Inc, Actavis plc, Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company and Cubist Pharmaceuticals, Inc.
KEY MARKET BENEFITS:
- Comprehensive analysis of factors that drive and restrict the growth of the global hospital infection therapeutics market is provided
- The report provides a comprehensive analysis of the current market and estimations which would enable the stakeholders to capitalize on prevailing market opportunities
- An in-depth analysis of key segments of the market demonstrate the types of drugs along with the applications in the hospital infection therapeutics market
- SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
- Region-wise hospital infection therapeutics market scenario is comprehensively analyzed in the report
Hospital Infection Therapeutics Market Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By Applications |
|
 By Region |
|
 Key Market Players | Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., Actavis plc, AstraZeneca plc, Pfizer, Inc., Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Sanofi S.A. |
Loading Table Of Content...
